Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: Analysis with magnetic resonance myocardial tagging

Paul Dubach, Jonathan Myers, Piero Bonetti, Thomas Schertler, Victor Froelicher, Doris Wagner, Markus Scheidegger, Matthias Stuber, Roger Luchinger, Juerg Schwitter, Otto Hess

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


Background: Recent data suggest that beta-blockers can be beneficial in subgroups of patients with chronic heart failure (CHF). For metoprolol and carvedilol, an increase in ejection fraction has been shown and favorable effects on the myocardial remodeling process have been reported in some studies. We examined the effects of bisoprolol fumarate on exercise capacity and left ventricular volume with magnetic resonance imaging (MRI) and applied a novel high-resolution MRI tagging technique to determine myocardial rotation and relaxation velocity. Methods: Twenty-eight patients (mean age, 57 ± 11 years; mean ejection fraction, 26 ± 6%) were randomized to bisoprolol fumarate (n = 13) or to placebo therapy (n = 15). The dosage of the drugs was titrated to match that of the the Cardiac Insufficiency Bisoprolol Study protocol. Hemodynamic and gas exchange responses to exercise, MRI measurements of left ventricular end-systolic and end-diastolic volumes and ejection fraction, and left ventricular rotation and relaxation velocities were measured before the administration of the drug and 6 and 12 months later. Results: After 1 year, heart rate was reduced in the bisoprolol fumarate group both at rest (81 ± 12 before therapy versus 61 ± 11 after therapy; P < .01) and peak exercise (144 ± 20 before therapy versus 127 ± 17 after therapy; P < .01), which indicated a reduction in sympathetic drive. No differences were observed in heart rate responses in the placebo group. No differences were observed within or between groups in peak oxygen uptake, although work rate achieved was higher (117.9 ± 36 watts versus 146.1 ± 33 watts; P < .05) and exercise time tended to be higher (9.1 ± 1.7 minutes versus 11.4 ± 2.8 minutes; P = .06) in the bisoprolol fumarate group. A trend for a reduction in left ventricular end-diastolic volume (-54 mL) and left ventricular end-systolic volume (-62 mL) in the bisoprolol fumarate group occurred after 1 year. Ejection fraction was higher in the bisoprolol fumarate group (25.0 ± 7 versus 36.2 ± 9%; P < .05), and the placebo group remained unchanged. Most changes in volume and ejection fraction occurred during the latter 6 months of treatment. With myocardial tagging, insignificant reductions in left ventricular rotation velocity were observed in both groups, whereas relaxation velocity was reduced only after bisoprolol fumarate therapy (by 39%; P < .05). Conclusion: One year of bisoprolol fumarate therapy resulted in an improvement in exercise capacity, showed trends for reductions in end-diastolic and end-systolic volumes, increased ejection fraction, and significantly reduced relaxation velocity. Although these results generally confirm the beneficial effects of beta-blockade in patients with chronic heart failure, they show differential effects on systolic and diastolic function.

Original languageEnglish (US)
Pages (from-to)676-683
Number of pages8
JournalAmerican heart journal
Issue number4
StatePublished - 2002
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Effects of bisoprolol fumarate on left ventricular size, function, and exercise capacity in patients with heart failure: Analysis with magnetic resonance myocardial tagging'. Together they form a unique fingerprint.

Cite this